Summit completes dosing in PhaseOut DMD

Summit Therapeutics has announced it has completed dosing participants in its Phase II PhaseOut DMD trial. The 48-week trial, is assessing the safety and efficacy of their utrophin modulator, ezutromid, in boys with Duchenne muscular dystrophy. Participants who have opted to join the extension phase of this study are continuing to receive ezutromid.

Summit previously reported positive results from their 24-week interim data. The company plan to report preliminary results from their 48-week data during Q3 of 2018.

For more information please read Summit’s press release.